,32 In 2022, a selective allosteric inhibitor targeting the TYK2 pseudokinase domain (deucravacitinib; BMS-986165) was approved by the U.S. Food and Drug Administration (FDA) for use in psoriasis.33 Here, TYK2 is linked to psoriasis.